Mölndal, Sweden - June 13, 2024 -Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a Memorandum of Understanding with the American medtech company Coapt LLC, with the intention to provide Integrum the possibility to combine Coapt's pattern recognition technology with the continued development of e-OPRATM Implant System.

Coapt is the leading developer of advanced control solutions for prosthetics. Their primary product is a pattern recognition intent decoder system, called Complete Control, designed to enhance the functionality and user experience of upper-limb prostheses, allowing seamless and personalized movements. The pattern recognition system uses machine learning algorithms, a form of artificial intelligence, or AI, to interpret electrical signals from the residual muscles of the amputee, which are then translated into movement. Complete Control continuously analyzes these signals, known as electromyographic signals, or EMG, to determine the intended movements of the user, allowing for more natural and intuitive control of the prosthetic limb.

Integrum is developing the e-OPRATM Implant System, the world's first upper-limb prosthetic control system using wired tissue-embedded electrodes. e-OPRATM uses an implanted electrode system that both record and stimulate nerves and muscle tissues. By connecting this system with Coapt's pattern recognition technology, Integrum aims to further improve the functionality of e-OPRATM.

"Coapt systems have been a complementary technology to prostheses users with Integrum's OPRA® Implant System for some time now. This agreement further strengthens the working collaboration between our two companies and will result in the best possible solutions and future with e-OPRATM and Coapt." Says Blair Lock, CEO of Coapt.

"By complementing the current control system of the e-OPRATM with Coapt's world leading pattern recognition system, we aim to refine the movement control of our implant system further and improve prothesis control. Together with Coapt, I am convinced we will deliver the best possible options for arm amputees, outperforming today's technology. It might sound like science fiction, but it is happening now!" says Rickard Brånemark, CEO of Integrum.

For more information, please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se

Jörgen Svanström, CFO
Phone: + 46 (0) 70 734 96 60
E-mail: Jorgen.svanstrom@integrum.se

Certified Adviser

Carnegie Investment Bank AB (publ) is Certified Adviser.

About Integrum

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/. 

About Coapt

Coapt, LLC is a privately held company based in Chicago, USA with a research subsidiary, Liberating Technologies, Inc. in Boston, USA. Coapt was founded in 2012 and quickly launched Complete Control, an FDA Class II-cleared myoelectric, machine learning prosthesis control system. This flagship product--now in its second generation--is the first technology to allow users to naturally control their advanced, prosthetic arms and hands. Complete Control leverages clinically developed artificial intelligence to learn and adapt to users' unique muscle signal patterns and provide intuitive control for bionic upper limbs. Coapt's myoelectric pattern recognition products are compatible with over 450 unique prosthetic limb configurations. In addition to Coapt's preeminent product line, the company has established deep industry partnerships and a robust academic research portfolio. To learn more, please visit https://coaptengineering.com/



(c) 2024 Cision. All rights reserved., source Press Releases - English